What is the appropriate diagnostic work‑up and risk‑adapted management for an adult male in his sixth decade presenting with elevated hemoglobin and hematocrit consistent with polycythemia?

Diagnostic Work-Up and Risk-Adapted Management of Polycythemia in an Adult Male

Initial Diagnostic Confirmation and Laboratory Assessment

Order JAK2 mutation testing (both V617F and exon 12) immediately as the first-line diagnostic test, because this mutation is present in >95% of polycythemia vera cases and provides definitive differentiation between primary and secondary erythrocytosis. 1, 2, 3, 4

Essential First-Line Laboratory Tests

• Complete blood count with red cell indices, reticulocyte count, and manual differential to confirm sustained hemoglobin/hematocrit elevation and assess for accompanying thrombocytosis (present in ~50% of PV) or leukocytosis (present in ~49% of PV). 1, 5, 2, 4

• Serum erythropoietin (EPO) level to distinguish primary from secondary polycythemia: low or inappropriately normal EPO has >90% specificity for PV, while elevated EPO suggests secondary causes. 1, 2

• Serum ferritin, iron, and transferrin saturation because iron deficiency can coexist with erythrocytosis and mask the true hemoglobin elevation in PV; low MCV with elevated RBC count is a strong clue for PV with iron depletion. 1, 5, 2

• Peripheral blood smear review by a qualified hematologist to identify abnormal morphology and assess for left shift or other myeloproliferative features. 5, 2

Critical Diagnostic Pitfall

• Do not exclude PV based on normal EPO levels alone—EPO sensitivity for PV is only 64-70%, so normal EPO with elevated hemoglobin still requires JAK2 testing. 1

• Do not overlook iron deficiency masking PV: when iron deficiency superimposes on PV, hemoglobin may appear deceptively normal or only mildly elevated despite true polycythemia; microcytosis (MCV <80 fL) with thrombocytosis, leukocytosis, or splenomegaly should trigger immediate PV work-up regardless of hemoglobin level. 1

---

Systematic Evaluation for Secondary Causes

If JAK2 is negative or EPO is elevated, systematically evaluate for secondary polycythemia before concluding the work-up. 1, 2

Hypoxia-Driven Causes (Most Common)

• Obtain detailed smoking history and measure carboxyhemoglobin if applicable—smoker's polycythemia from chronic carbon monoxide exposure is the most common secondary cause and resolves with smoking cessation. 1, 2

• Order sleep study if obstructive sleep apnea is suspected based on history of snoring, witnessed apneas, or daytime somnolence—nocturnal hypoxemia drives compensatory erythrocytosis. 1, 2

• Arterial oxygen saturation and chest X-ray to rule out chronic lung disease (COPD, interstitial lung disease) or right-to-left cardiopulmonary shunts. 1, 2

• Consider high-altitude residence: physiologic adaptation increases hemoglobin by 0.2-4.5 g/dL depending on elevation (e.g., +1.9 g/dL at 3,000 meters); WHO PV diagnostic thresholds must be adjusted for altitude. 1, 5, 2

Hypoxia-Independent Causes

• Abdominal ultrasound or CT to screen for EPO-producing tumors: renal cell carcinoma, hepatocellular carcinoma, uterine leiomyomas, pheochromocytoma, meningioma, or parathyroid carcinoma. 1, 2

• Medication review for exogenous testosterone, anabolic steroids, or administered erythropoietin—these agents cause secondary erythrocytosis and require dose adjustment or discontinuation. 1, 5, 2

• Renal function testing to evaluate for post-renal-transplant erythrocytosis if the patient is a transplant recipient. 1, 2

Relative Polycythemia (Plasma Volume Depletion)

• Assess hydration status by reviewing fluid intake history, recent losses (diarrhea, vomiting), and diuretic use—dehydration is the most common cause of elevated hematocrit without true increase in red cell mass. 1, 2

---

Diagnostic Criteria for Polycythemia Vera

PV diagnosis requires EITHER (a) both major criteria PLUS one minor criterion, OR (b) the first major criterion PLUS two minor criteria. 1, 5, 2, 3, 4

Major Criteria

1. Elevated hemoglobin >18.5 g/dL or hematocrit >52% in men (>16.5 g/dL or >49% in women). 1, 5, 2, 4

2. Presence of JAK2 mutation (V617F in ~95% of cases; exon 12 mutations in another 2-4%). 1, 2, 3, 4

Minor Criteria

1. Bone marrow biopsy showing hypercellularity with trilineage growth (panmyelosis). 1, 2, 3

2. Subnormal serum erythropoietin level (below the laboratory reference range). 1, 2, 3

3. Endogenous erythroid colony formation in vitro (rarely performed due to limited availability). 1, 2

When to Perform Bone Marrow Biopsy

• Bone marrow biopsy is required if JAK2 mutation is positive to confirm PV diagnosis and assess for trilineage myeloproliferation. 5

• Consider bone marrow biopsy if diagnosis remains unclear after initial work-up to exclude other myeloid neoplasms. 5

---

Risk Stratification and Management of Confirmed Polycythemia Vera

All patients with confirmed PV should receive two cornerstone therapies: (1) therapeutic phlebotomy to maintain hematocrit strictly <45%, and (2) low-dose aspirin 81-100 mg daily (if no contraindications). 1, 5, 3, 4

Risk Stratification

• High-risk patients (age ≥60 years OR prior thrombotic event) require cytoreductive therapy with hydroxyurea or interferon in addition to phlebotomy and aspirin. 1, 4

• Low-risk patients (age <60 years AND no prior thrombosis) are managed with phlebotomy and aspirin alone. 4

Evidence for Hematocrit Target <45%

• The CYTO-PV trial demonstrated that maintaining hematocrit <45% significantly reduces thrombotic events (2.7% vs 9.8%, P=0.007) compared with a target of 45-50%. 5

• This 45% threshold is absolute and evidence-based for PV—it does not apply to secondary erythrocytosis, where higher targets (55-60%) may be appropriate because elevated hematocrit serves a compensatory physiological role. 5

Phlebotomy Protocol

• When performing therapeutic phlebotomy, replace the removed blood volume with an equal amount of intravenous saline to prevent hemoconcentration and reduce stroke risk. 5

• Monitor iron status closely: iron deficiency is expected with phlebotomy therapy in PV and is actually therapeutic (it limits erythropoiesis); however, severe iron deficiency with microcytosis increases stroke risk, so balance is required. 1, 5

Cytoreductive Therapy Indications

• Hydroxyurea is first-line cytoreductive therapy for high-risk patients or those with persistent symptoms despite phlebotomy. 3, 4

• Pegylated interferon-alfa is an alternative for younger patients or those intolerant of hydroxyurea. 3, 4

• Ruxolitinib (JAK inhibitor) is reserved for patients intolerant of or resistant to hydroxyurea; it effectively alleviates pruritus and reduces splenomegaly. 3, 4

---

Management of Secondary Polycythemia

Treatment of the underlying condition is the primary management strategy for secondary polycythemia—phlebotomy is rarely indicated and can be harmful. 1, 5, 2

When Phlebotomy is Contraindicated in Secondary Polycythemia

• Routine or repeated phlebotomies are explicitly contraindicated because they cause iron depletion, decreased oxygen-carrying capacity, and paradoxically increase stroke risk. 1, 5, 2

• Phlebotomy is contraindicated when the underlying cause is cyanotic congenital heart disease, as right-to-left shunting drives a physiologic compensatory erythrocytosis that should not be interrupted. 5

Rare Exceptions: When Phlebotomy May Be Considered

Phlebotomy is indicated ONLY when ALL of the following criteria are met: 1, 5, 2

1. Hemoglobin >20 g/dL AND hematocrit >65%
2. Documented symptoms of hyperviscosity (headache, visual disturbances, dizziness, confusion, bleeding)
3. Patient is adequately hydrated (dehydration has been excluded)
4. Iron deficiency has been excluded (transferrin saturation ≥20%)
5. Hematocrit remains elevated above baseline despite hydration

• First-line therapy for suspected hyperviscosity is aggressive rehydration with oral fluids or intravenous normal saline, NOT phlebotomy. 5

Specific Management by Etiology

• Smoker's polycythemia: smoking cessation is the primary treatment; risk reduction begins within 1 year and returns to baseline after 5 years. 1, 2

• Obstructive sleep apnea: CPAP therapy to correct nocturnal hypoxemia. 1, 2

• COPD: optimize pulmonary management; supplemental oxygen if arterial saturation <92%. 1, 5, 2

• Testosterone therapy: dose adjustment or temporary discontinuation with close hematocrit monitoring. 5, 2

• EPO-producing tumors: tumor surveillance imaging every 3-6 months per oncologic protocols. 1

Iron Management in Secondary Polycythemia

• If transferrin saturation <20%, initiate cautious oral iron supplementation with close hemoglobin monitoring—iron deficiency mimics hyperviscosity symptoms but requires the opposite treatment. 1, 5

• Iron-deficient red blood cells have reduced oxygen-carrying capacity and deformability, which increases stroke risk even in the presence of elevated hemoglobin. 1, 5, 2

---

Immediate Referral Indications

Refer immediately to hematology if any of the following are present: 5, 2

• Positive JAK2 mutation (confirms PV and requires specialist management)
• Hemoglobin >20 g/dL with symptoms of hyperviscosity (urgent consultation needed)
• Unexplained splenomegaly with elevated blood counts
• Diagnosis remains unclear after initial work-up
• Unexplained cytopenias in one or more lineages alongside erythrocytosis (suggests myeloid neoplasm)

---

Monitoring Strategy

For Confirmed PV

• Monitor CBC monthly during initial phlebotomy phase until hematocrit stabilized <45%. 1
• Monitor CBC every 3 months once stable on maintenance therapy. 1
• Annual assessment for splenomegaly, thrombotic events, and progression to myelofibrosis or acute leukemia (12.7% develop myelofibrosis; 6.8% develop AML over time). 4

For Stable Secondary Polycythemia

• Monitor CBC and cause-specific parameters every 3-6 months once stable. 1
• Monitor monthly for the first 3 months if newly diagnosed or unstable. 1

For Borderline or Stable Erythrocytosis (JAK2-Negative, Hct <65%)

• Serial hematologic assessment every 6-12 months to detect progression or complications. 5
• If hemoglobin rises significantly despite treatment of underlying cause, consider repeat JAK2 testing to exclude PV. 1

---

Common Pitfalls to Avoid

• Do not assume normal EPO excludes PV—EPO sensitivity is only 64-70%; proceed with JAK2 testing. 1

• Do not overlook coexisting iron deficiency—microcytosis with elevated RBC count may indicate PV with iron depletion, not simple iron deficiency. 1, 5, 2

• Do not perform aggressive phlebotomy in secondary polycythemia—this causes harm (iron depletion, reduced oxygen-carrying capacity, increased stroke risk). 1, 5, 2

• Do not perform phlebotomy without equal-volume fluid replacement—this raises hemoconcentration and stroke risk. 5

• Do not use standard PV diagnostic thresholds at high altitude without adjustment—physiologic adaptation can increase hemoglobin by 0.2-4.5 g/dL depending on elevation. 5

• Beware of false reassurance from "normal" EPO in chronic hypoxic states—EPO may normalize after hemoglobin stabilizes at a compensatory higher level, potentially mimicking PV. 1